Navigation Links
GUMC researcher creates first Web-interactive CME course for physicians on pharmaceutical marketing
Date:3/31/2009

Washington, DC Difficult-to-remember generic drug names. Unregulated continuing medical education talks for physicians. These are only two of the strategies used by some in the pharmaceutical industry to influence the prescribing habits of doctors, according to a Georgetown University Medical Center researcher and director of PharmedOut, an initiative aimed at increasing physician access to unbiased information about drugs. These and other marketing efforts are explored in a newly created, free, web-based, accredited course to help prescribers assess how marketing affects their own beliefs about drugs and to increase awareness of pharmaceutical promotional techniques. The project was created by PharmedOut and funded through the Attorney General Consumer and Prescriber Education Grant Program.

"We want to educate doctors about the many ways pharmaceutical companies attempt to influence our knowledge of drugs and our prescribing behavior," said the course's co-creator, Adriane Fugh-Berman, MD, director of PharmedOut and associate professor of Physiology & Biophysics at GUMC.

The online course, titled "Pharmalyzer -- -- Are You Prescribing Under the Influence?" is accredited for three continuing medical education (CME) credits.* The module may be accessed through PharmedOut.org or the Federation of State Medical Boards (FSMB).

On the site, the authors outline the many marketing tactics used by pharmaceutical companies, which they say "attempt to influence our knowledge of drugs and our prescribing behavior though many channels, including personal relationships, publications, meetings, and events."

In one section of the online course, viewers are asked to name drugs associated with highly recognizable images from TV and print advertising without drug names are shown and viewers are asked to name the drug being representing.

"The fact that we can name the products means that the ads have served their purpose," explain the authors.

Another compelling example demonstrating the influence of pharmaceutical marketing is a list of diseases and conditions the course says were created by the pharmaceutical industry such as GERD, erectile dysfunction, excessive sleepiness, restless legs syndrome, overactive bladder syndrome, social anxiety disorder and osteopenia.

The authors explain, "We associate these conditions with a specific drug because the companies that made each of these drugs invented or renamed the condition. In marketing, this is called disease branding. GERD, for example, used to be called heartburn, and Social Anxiety Disorder used to be called shyness."

In another section, viewers are asked for the generic names of popular drugs such as Lipitor, Nexium, Advair, Plavix, and Singulair, and note that marketing techniques used by pharmaceutical companies make brand names of drugs easier to remember.

"Pharmaceutical companies prefer generic names that are difficult to remember, pronounce, and spell to encourage the use of the brand name," says Tony Scialli, MD, adjunct professor of Obstetrics and Gynecology at GUMC, and a member of PharmedOut. Scialli is also vice-president of Tetra Tech Sciences.

The course also includes information about "detailing," a term used to describe visits made by drug sales representatives to prescribers. The authors suggest, "Barring drug reps from your office is the best way to avoid being influenced."

The authors also alert physicians about CME talks and grand rounds, "although often funded by industry, [CME talks and grand rounds] are not regulated by the FDA. Presentations at industry-funded CME are often laced with marketing messages."

"This comprehensive course explores the tools the pharmaceutical industry employs to sell their drugs," says Fugh-Berman. "Most patients trust their doctors to recommend the best therapies, but patients and their doctors may not be aware of the influence this powerful industry is having on their care."

In addition to Fugh-Berman and Scialli, Scott Pegler, B Pharm, principal pharmacist and medicines information manager for Swansea NHS Trust in the U.K., is a co-author of this CME module. The authors make the disclosures that follow. Fugh-Berman occasionally testifies as a paid expert witness in litigation involving pharmaceutical marketing practices. Scialli has been a paid consutant for Merck, Theravance, Toyama, AMAG Pharmaceuticals, Abbott, Hollis-Eden, Cynthus, Procter & Gamble and GlaxoSmithKline. Pegler reports no potential conflicts.


'/>"/>

Contact: Karen Mallet
km463@georgetown.edu
215-514-9751
Georgetown University Medical Center
Source:Eurekalert

Related medicine news :

1. Researchers Successfully Create Computer-Simulated Model for Evaluating Artificial Pancreas
2. Yale researchers discover mechanism for
3. MSU researcher links cholesterol crystals to cardiovascular attacks
4. Three Johns Hopkins researchers named Howard Hughes Medical Institute early career scientists
5. Researchers decipher blood stem cell attachment, communication
6. Researchers studying hearing loss find auditory regions of the brain convert to the sense of touch
7. UIC researchers measure health effects of Chicagos waterways
8. U-M researchers idea jells into potential new disease-detection method
9. Focus on treating malnutrition in cancer patients, researchers say
10. Researchers Suspect Genetic Link to COPD
11. Syracuse University researchers build a new surface material that resists biofilm growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... , ... The Case Management Society of America (CMSA) will install six new ... membership has elected their upcoming President-Elect, Secretary, Treasurer and two Directors to serve on ... Advisory position has also been added to the BOD, per an appointment made by ...
(Date:3/27/2017)... ... March 27, 2017 , ... EpiGentek ... to pursue the recent RNA methylation “gold rush” with their established portfolio of ... newfound characteristics of N6-methyladenosine, or m6A , RNA methylation has received a ...
(Date:3/27/2017)... Foothill Ranch, California (PRWEB) , ... March 27, 2017 , ... ... company’s commitment to its customers. First National Capital has added 10 new sales professionals ... to grow its sales positions by 15 additional new hires over the course of ...
(Date:3/27/2017)... RICHEY, Fla. (PRWEB) , ... March 27, 2017 ... ... drug overdose deaths soared 167%,(1) with opioids alone responsible for over 33,000 of ... Kevin McCarty has sponsored Assembly Bill (AB) 1512, which proposes a tax on ...
(Date:3/25/2017)... ... March 25, 2017 , ... Norland at Swissray is pleased to announce the ... subjects. The ELITE DXA has an active scan window, which is more than double ... fit in the scan area could not undergo an accurate total body bone density or ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... Calif. , March 27, 2017  Sanderling ... acquired by Ethicon, a division of Johnson & ... System for the treatment of gastro-esophageal reflux disease ... sphincter augmentation (MSA) technology and the procedure is ... centers. Torax Medical was founded by ...
(Date:3/27/2017)... SAN DIEGO and VANCOUVER, British Columbia, March 27, ... SPHS ) (the "Company" or "Sophiris"), a clinical ... treatment of patients with urological diseases, today reported ... and key corporate highlights. Key ... in Clinical Development for Localized Prostate Cancer. During ...
(Date:3/27/2017)... 27, 2017 FinancialBuzz.com News Commentary  ... According to a new report by Arcview Market ... , grew 34 percent to $6.7 billion and can be expected to ... the next five years, from $6.7 billion in 2016, to $22.6 billion ... be able to purchase cannabis without a doctor,s recommendation. Voters in ...
Breaking Medicine Technology: